ANX-201 Drug Combination Demonstrates Synergistic Activity Against Human And Bird Flu Viruses

ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that it presented
results demonstrating synergistic activity against human and avian
influenza (bird flu) viruses when the Company's broad-spectrum antiviral
drug candidate, ANX-201 (thiophosphonoformic acid), was combined with
oseltamivir phosphate (Tamiflu(R)) in preclinical tests. ANX-201 also
demonstrated single agent antiviral activity against these viruses. The
results were presented at the International Conference on Antiviral
Research (ICAR) in Palm Springs, CA on Wednesday, May 2nd.


"These results suggest we can simultaneously improve efficacy and lower
dosages with a two drug regimen of ANX-201 and Tamiflu," said Evan M.
Levine, chief executive officer of ADVENTRX. "We intend to continue to
investigate the use of ANX-201 in avian flu."



As a single agent, ANX-201 showed dose-dependent antiviral activity
against human, equine and avian influenza virus. Fixed-dose combinations of
ANX-201 and the neuraminidase inhibitor Tamiflu produced a supra-additive,
or synergistic, antiviral activity against the human and avian influenza
viruses, as demonstrated by an overall lowering of the drug concentrations
required to achieve virus inhibition. ANX-201 dosage could be reduced up to
10 fold against human influenza strains H3N2 and H1N1, and up to 100 fold
against avian influenza strain H5N2 when administered in combination with
Tamiflu. Tests were performed in vitro using standard cell-based influenza
infectivity assays. A copy of the poster presentation is available for
download from the "Resources" section of the Company's web site at
adventrx under "Publications."



About ANX-201



ANX-201 (thiophosphonoformic acid) is a pyrophosphate analog and member
of a new class of reverse transcriptase inhibitor (RTI) for HIV. ANX-201
has shown activity against HIV drug-resistant clinical isolates and has
shown synergy with nucleoside RTIs (NRTIs) in preclinical studies. The
resistance profile of ANX-201 is unique among approved RTIs and contains
mutations that have been shown to resensitize NRTI-resistant virus. In
preclinical studies, ANX-201 has shown broad-spectrum antiviral activity
against HIV-1, HIV-2, human and avian influenza viruses, and herpes simplex
viruses 1 and 2 (HSV-1 and HSV-2). ADVENTRX plans to initiate a Phase 1/2
clinical trial of ANX-201 as a component of multi-drug therapy for the
treatment of HIV during 2007.
















About ADVENTRX Pharmaceuticals



ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at adventrx.



Forward Looking Statement



ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the validity of research results; the risk that preclinical
results are not indicative of the success of subsequent clinical trials and
that products will not perform as preclinical data suggests or as otherwise
anticipated; unexpected adverse side effects or inadequate therapeutic
efficacy of ANX-201 and other uncertainties inherent in the drug
development process; the timing and success of clinical trials;
difficulties or delays in developing, testing, manufacturing, and obtaining
regulatory approval for ANX-201, including receiving necessary regulatory
approvals for a Phase 1/2 clinical trial of ANX-201; the risk that ADVENTRX
will be unable to raise sufficient capital to fund the projects necessary
to meet its anticipated or stated goals and milestones, including funding
the continued development of ANX-201 for the treatment of HIV or human or
avian influenza; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at sec. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in this
press release, to reflect events or circumstances arising after the date on
which it was made.


ADVENTRX Pharmaceuticals, Inc.

adventrx


View drug information on Tamiflu capsule.